Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

Frequency and clinicopathologic correlates of KRAS amplification in non-small cell lung carcinoma.

Wagner PL, Stiedl AC, Wilbertz T, Petersen K, Scheble V, Menon R, Reischl M, Mikut R, Rubin MA, Fend F, Moch H, Soltermann A, Weder W, Altorki NK, Perner S.

Lung Cancer. 2011 Oct;74(1):118-23. doi: 10.1016/j.lungcan.2011.01.029. Epub 2011 Apr 8.

PMID:
21477882
2.

The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients.

Camps C, Jantus-Lewintre E, Cabrera A, Blasco A, Sanmartín E, Gallach S, Caballero C, del Pozo N, Rosell R, Guijarro R, Sirera R.

Lung Cancer. 2011 Jun;72(3):365-9. doi: 10.1016/j.lungcan.2010.09.005. Epub 2010 Nov 12.

PMID:
21074889
3.

Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).

Lim EH, Zhang SL, Li JL, Yap WS, Howe TC, Tan BP, Lee YS, Wong D, Khoo KL, Seto KY, Tan L, Agasthian T, Koong HN, Tam J, Tan C, Caleb M, Chang A, Ng A, Tan P.

J Thorac Oncol. 2009 Jan;4(1):12-21. doi: 10.1097/JTO.0b013e3181913e28.

4.

In situ evidence of KRAS amplification and association with increased p21 levels in non-small cell lung carcinoma.

Wagner PL, Perner S, Rickman DS, LaFargue CJ, Kitabayashi N, Johnstone SF, Weir BA, Meyerson M, Altorki NK, Rubin MA.

Am J Clin Pathol. 2009 Oct;132(4):500-5. doi: 10.1309/AJCPF10ZUNSOLIFG.

PMID:
19762526
5.

Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?

Macerelli M, Caramella C, Faivre L, Besse B, Planchard D, Polo V, Ngo Camus M, Celebic A, Koubi-Pick V, Lacroix L, Pignon JP, Soria JC.

Lung Cancer. 2014 Mar;83(3):383-8. doi: 10.1016/j.lungcan.2013.12.013. Epub 2014 Jan 3.

PMID:
24439569
6.

Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.

Metro G, Chiari R, Bennati C, Cenci M, Ricciuti B, Puma F, Flacco A, Rebonato A, Giannarelli D, Ludovini V, Bellezza G, Ferolla P, Minotti V, Crinò L.

Clin Lung Cancer. 2014 Jan;15(1):86-92. doi: 10.1016/j.cllc.2013.08.002. Epub 2013 Oct 17.

PMID:
24139827
7.

Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).

Cadranel J, Mauguen A, Faller M, Zalcman G, Buisine MP, Westeel V, Longchampt E, Wislez M, Coudert B, Daniel C, Chetaille B, Michiels S, Blons H, Solassol J, De Fraipont F, Foucher P, Urban T, Lacroix L, Poulot V, Quoix E, Antoine M, Danton G, Morin F, Chouaid C, Pignon JP.

J Thorac Oncol. 2012 Oct;7(10):1490-502.

8.
9.

MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort.

Beau-Faller M, Ruppert AM, Voegeli AC, Neuville A, Meyer N, Guerin E, Legrain M, Mennecier B, Wihlm JM, Massard G, Quoix E, Oudet P, Gaub MP.

J Thorac Oncol. 2008 Apr;3(4):331-9. doi: 10.1097/JTO.0b013e318168d9d4.

10.

Evaluation of Kras gene mutation and copy number gain in non-small cell lung cancer.

Sasaki H, Hikosaka Y, Kawano O, Moriyama S, Yano M, Fujii Y.

J Thorac Oncol. 2011 Jan;6(1):15-20. doi: 10.1097/JTO.0b013e31820594f0.

11.

Molecular alterations in non-small cell lung carcinomas of the young.

VandenBussche CJ, Illei PB, Lin MT, Ettinger DS, Maleki Z.

Hum Pathol. 2014 Dec;45(12):2379-87. doi: 10.1016/j.humpath.2014.08.005. Epub 2014 Sep 2.

PMID:
25288236
12.

Assessment of MAGE-A expression in resected non-small cell lung cancer in relation to clinicopathologic features and mutational status of EGFR and KRAS.

Ayyoub M, Memeo L, Alvarez-Fernández E, Colarossi C, Costanzo R, Aiello E, Martinetti D, Valmori D.

Cancer Immunol Res. 2014 Oct;2(10):943-8. doi: 10.1158/2326-6066.CIR-13-0211. Epub 2014 May 27.

13.

Identification of transcriptional subgroups in EGFR-mutated and EGFR/KRAS wild-type lung adenocarcinoma reveals gene signatures associated with patient outcome.

Planck M, Isaksson S, Veerla S, Staaf J.

Clin Cancer Res. 2013 Sep 15;19(18):5116-26. doi: 10.1158/1078-0432.CCR-13-0928. Epub 2013 Aug 12.

14.

Mutations of EGFR or KRAS and expression of chemotherapy-related genes based on small biopsy samples in stage IIIB and IV inoperable non-small cell lung cancer.

Deng LL, Deng HB, Lu CL, Guo Y, Wang D, Yan CH, Lv X, Shao YX.

J Cancer Res Clin Oncol. 2014 Dec;140(12):2097-105. doi: 10.1007/s00432-014-1751-y. Epub 2014 Jul 4.

PMID:
24994038
15.

A pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative non-small cell lung cancer.

Cuffe S, Bourredjem A, Graziano S, Pignon JP, Domerg C, Ezzalfani M, Seymour L, Strevel E, Burkes R, Capelletti M, Jänne PA, Tsao MS, Shepherd FA.

J Thorac Oncol. 2012 Jun;7(6):963-72. doi: 10.1097/JTO.0b013e31824fe9e6.

16.

Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer.

Li Y, Li Y, Yang T, Wei S, Wang J, Wang M, Wang Y, Zhou Q, Liu H, Chen J.

PLoS One. 2013;8(1):e52093. doi: 10.1371/journal.pone.0052093. Epub 2013 Jan 14.

17.

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcome in resected non-small cell lung cancer patients.

Ragusa M, Vannucci J, Ludovini V, Bianconi F, Treggiari S, Tofanetti FR, Flacco A, Colella R, Sidoni A, Crinò L, Puma F.

Am J Clin Oncol. 2014 Aug;37(4):343-9. doi: 10.1097/COC.0b013e31827a7e7a.

PMID:
23357969
18.

Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.

Sunaga N, Kaira K, Imai H, Shimizu K, Nakano T, Shames DS, Girard L, Soh J, Sato M, Iwasaki Y, Ishizuka T, Gazdar AF, Minna JD, Mori M.

Oncogene. 2013 Aug 22;32(34):4034-42. doi: 10.1038/onc.2012.402. Epub 2012 Sep 10.

19.

Prognostic value analysis of mutational and clinicopathological factors in non-small cell lung cancer.

Li C, Hao L, Li Y, Wang S, Chen H, Zhang L, Ke B, Yin Y, Suo H, Sun B, Zhang B, Wang C.

PLoS One. 2014 Sep 8;9(9):e107276. doi: 10.1371/journal.pone.0107276. eCollection 2014.

20.

Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?

Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA.

J Clin Oncol. 2010 Nov 1;28(31):4769-77. doi: 10.1200/JCO.2009.27.4365. Epub 2010 Oct 4. Review.

PMID:
20921461

Supplemental Content

Support Center